| Biological Information | |
|---|---|
| Background Information: | SETD2 (SET Domain Containing 2) is a histone methyltransferase that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the lysine 36 residue of histone H3 (H3K36), leading to the formation of mono-, di-, and trimethylated H3K36. SETD2 is a member of the SET domain-containing protein family and is the only known enzyme that specifically methylates H3K36. SETD2 plays a crucial role in the regulation of transcriptional elongation by methylating H3K36 on actively transcribed genes, and it is involved in the recruitment of transcriptional elongation factors, including FACT and the PAF complex.
SETD2 is an important epigenetic protein with potential therapeutic applications. Its inhibition has been shown to suppress tumor growth and improve the response to chemotherapy in preclinical models of cancer. |
| Target Class: | Epigenetic Protein |
| Accession Number: | Refer to CoA for Accession Number |
| Target Name: | SETD2 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 1 year at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
SETD2
N-terminal 6His-tagged recombinant, human SETD2 amino acids 843-1208.
Datasheets
EPI055 Datasheet
View Document